Literature DB >> 31896516

Neutralizing tumor-promoting inflammation with polypeptide-dexamethasone conjugate for microenvironment modulation and colorectal cancer therapy.

Sheng Ma1, Wantong Song2, Yudi Xu3, Xinghui Si1, Dawei Zhang2, Shixian Lv4, Chenguang Yang2, Lili Ma2, Zhaohui Tang1, Xuesi Chen5.   

Abstract

Tumor is known as "a wound that does not heal". Tumor-promoting inflammation plays a crucial role in carcinogenesis, tumor progression, tumor metastasis, as well as chemotherapy resistance. Therefore, reducing tumor-promoting inflammation may be a key aspect in targeting the tumor microenvironment for cancer therapy. Dexamethasone (DEX), a commercial drug in the treatment of many different inflammatory diseases, can effectively inhibit the release of substances causing inflammation. However, as a corticosteroid medication, direct use of DEX results in many severe side effects. In this study, a redox and pH dual sensitive polypeptide-DEX conjugate (L-SS-DEX) was synthesized, and the L-SS-DEX dramatically increased the tumoral accumulation of DEX in murine colorectal cancer model (CT26) compared to free DEX. Importantly, at equal dose (10 mg/kg), L-SS-DEX showed superior antitumor activity over free DEX: 86% tumor suppression rate of L-SS-DEX treatment group compared to 49% of free DEX treatment group. Further analysis of the tumor tissues showed that cyclooxygenase-2 (COX-2) and α-smooth muscle actin (α-SMA) were significantly reduced after the L-SS-DEX treatment compared with control groups. In addition, the immunosuppressive microenvironment of the CT26 tumor was effectively relieved after L-SS-DEX treatment, characterized by increased CD8+ T cell infiltration, increased ratio of M1 over M2 macrophages, as well as markedly decrease in regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). The above results suggest that anti-inflammatory drugs hold great potential in modulating the tumor microenvironment when delivered properly, and can also result in significant tumor inhibition effects. Since dramatic amounts of anti-inflammatory drugs have been used in clinic, our results may provide improved tumor therapy options of using anti-inflammatory drugs for cancer therapy.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-Inflammation; Dexamethasone; Polypeptide; Tumor microenvironment

Mesh:

Substances:

Year:  2019        PMID: 31896516     DOI: 10.1016/j.biomaterials.2019.119676

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  12 in total

1.  Functional cRGD-Conjugated Polymer Prodrug for Targeted Drug Delivery to Liver Cancer Cells.

Authors:  Ru Zhou; Mingzu Zhang; Jinlin He; Jian Liu; Xingwei Sun; Peihong Ni
Journal:  ACS Omega       Date:  2022-06-07

Review 2.  Supramolecular Self-Assembled Nanostructures for Cancer Immunotherapy.

Authors:  Zichao Huang; Wantong Song; Xuesi Chen
Journal:  Front Chem       Date:  2020-05-25       Impact factor: 5.221

Review 3.  Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection.

Authors:  Fan Tang; Yan Tie; Weiqi Hong; Yuquan Wei; Chongqi Tu; Xiawei Wei
Journal:  Ann Surg Oncol       Date:  2020-11-30       Impact factor: 5.344

4.  Ion drugs for precise orthotopic tumor management by in situ the generation of toxic ion and drug pools.

Authors:  Yushuo Feng; Ruixue Qin; Lihua Xu; Xiaoqian Ma; Dandan Ding; Shi Li; Lei Chen; Yaqing Liu; Wenjing Sun; Hongmin Chen
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

5.  Diosgenin From Dioscorea Nipponica Rhizoma Against Graves' Disease-On Network Pharmacology and Experimental Evaluation.

Authors:  Jingxin Xin; Wencong Cheng; Yongbing Yu; Juan Chen; Xinhuan Zhang; Shanshan Shao
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

Review 6.  Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer.

Authors:  Yitong Li; Zhenmei Chen; Jiahao Han; Xiaochen Ma; Xin Zheng; Jinhong Chen
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

Review 7.  Research Progress of Conjugated Nanomedicine for Cancer Treatment.

Authors:  Bin Zhao; Sa Chen; Ye Hong; Liangliang Jia; Ying Zhou; Xinyu He; Ying Wang; Zhongmin Tian; Zhe Yang; Di Gao
Journal:  Pharmaceutics       Date:  2022-07-21       Impact factor: 6.525

Review 8.  Recent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy.

Authors:  Xiufeng Cong; Jun Chen; Ran Xu
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29

9.  Combination of preoperative red cell distribution width and neutrophil to lymphocyte ratio as a prognostic marker for gastric cancer patients.

Authors:  Lei Fu; Qian Li; Qingxia Fan
Journal:  J Gastrointest Oncol       Date:  2021-06

Review 10.  Dexamethasone Conjugates: Synthetic Approaches and Medical Prospects.

Authors:  Natallia V Dubashynskaya; Anton N Bokatyi; Yury A Skorik
Journal:  Biomedicines       Date:  2021-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.